We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




US Laboratories Surveyed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 06 Jan 2011
The accuracy of laboratories in detecting and identifying malaria parasites and assessing malaria screening practices has been evaluated.

The American Proficiency Institute (API; Traverse City, MI, USA) has examined the diagnostic precision of laboratories in the US to identify different species of malaria parasites and assessed whether the correct follow-up procedures were practiced. More...


Malaria is usually diagnosed in the laboratory by microscopic examination of a stained thick and thin blood smear or by the use of a rapid diagnostic test (RDT). Malaria RDTs detect specific antigens (proteins) produced by malaria parasites, that are present in the blood of infected or recently infected individuals. Some RDTs can detect only one species of the malaria parasite, Plasmodium falciparum, while some also detect other species of the parasite, P. vivax, P. malariae and P. ovale. Blood for these tests are commonly obtained from a finger-prick.

API reviewed proficiency-testing data from 1999 to 2008 to determine the rates of unacceptable responses for detecting and identifying Plasmodium species, the parasites that cause malaria. Laboratories in the United States were better able to detect and identify P. falciparum than other types of parasite species. However, when assessing malaria screening practices among current proficiency testing providers, the review found that half of the surveyed laboratories failed to offer a complete diagnostic workup, 25.0% failed to screen both thick and thin slides, and 36.1% failed to issue a final report within 24 hours.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that approximately 1,500 cases of imported malaria are diagnosed each year in the US. Of these, 71% were acquired in Africa and about 41% were due to P. falciparum. In December 2010, an autochthonous case of P. falciparum malaria was diagnosed in a 31-year-old female resident of Jacksonville (FL, USA) who had no history of international travel.

Daniel C. Edson, M.S., M.T. (ASCP), API president and lead author of the report, said, "Malaria is a serious, sometimes fatal, disease and laboratories should be better prepared to identify various species of malaria parasites, the more rapidly patients may be treated and hopefully cured". The study was published in December 2010, in Lab Medicine.

Related Links:

American Proficiency Institute
CDC




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.